Celsion Corporation
Aug 3, 2010

Celsion Reports Second Quarter 2010 Financial Results and Provides Business Update

COLUMBIA, Md., Aug 03, 2010 /PRNewswire via COMTEX News Network/ -- Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox(R), Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox(R) is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.

"We continue to make substantial progress recruiting patients into our Phase III HEAT trial for ThermoDox(R). We continue to track well against our goal to complete enrollment by the end of this year," said Michael Tardugno, President and CEO of Celsion. "We have exceeded our goal of opening enrollment at 70 clinical trial sites with 74 enrolling world-wide. The Phase I/II DIGNITY trial of ThermoDox(R) in patients with recurrent chest wall breast cancer (RCW) also continues to advance. We are currently enrolling patients in the 50mg/m2 dosing cohort, which will be used to determine our therapeutic dose."

Financial Results

For the second quarter ended June 30, 2010, Celsion reported a net loss of $2.6 million, compared to a net loss of $4.6 million for the same period of 2009. For the first half of 2010, net cash used in operations was $6.8 million. Celsion reported a net loss of $8.8 million for the first half of 2010, compared to a net loss of $8.2 million for the same period of 2009. In the second quarter of 2010, Celsion recorded a $1.8 million non-cash benefit related to the change in the common stock warrant liability. In the same period of 2009, the Company recorded a non-cash indemnity reserve benefit of $0.5 million. In the first half of 2010, Celsion recorded a $0.3 million non-cash benefit related to the change in the common stock warrant liability. In the same period of 2009, the Company recorded a non-cash indemnity reserve benefit of $1.5 million.

The Company ended the quarter with a total of $5.7 million of cash and investments. On June 17, 2010, the Company secured a committed equity financing facility under which it may sell up to $15 million of common stock to Small Cap Biotech Value Ltd. over a 24 month period.

Recent Company Highlights

The Company is holding a conference call to provide a business update and discuss the second quarter 2010 results at 11:00 a.m. Eastern Time on August 3, 2010. To participate in the call, interested parties may dial 1-888-806-6230 (Toll free U.S./Canada) or 1-913-227-1353 (Toll/International) and use Conference ID: 1474955 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the Internet at http://www.celsion.com.

The call will be archived for replay on Tuesday, August 3, 2010 at 3:00 p.m. Eastern Time and will remain available until Tuesday, August 10, 2010. The replay can be accessed at 1-877-870-5176 (Toll free U.S./Canada) or 1-858-384-5517 (Toll/International) using Replay Pin: #1474955. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 3:00 p.m. on August 3, 2010.

About ThermoDox(R)

ThermoDox(R) in combination with hyperthermia has the potential to provide local tumor control and improve quality of life. ThermoDox(R) is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox(R) is being evaluated in a 600 patient global Phase III study at 74 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox(R) in combination with Radio Frequency Ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival and enrollment is anticipated to be completed by the end of this year. For recurrent chest wall breast cancer, ThermoDox(R) is being evaluated in a pivotal Phase I/II open-label, dose-escalating trial that is designed to measure durable local complete response at the tumor site. Celsion expects to fully enroll the Phase I portion of the study by the fourth quarter of 2010. Additional information on the Company's ThermoDox(R) clinical studies may be found at http://www.clinicaltrials.gov .

About Celsion

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.


    Investor Contact
    Marcy Nanus
    The Trout Group
    646-378-2927 or mnanus@troutgroup.com


For more information on Celsion, visit our website: http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

                                        Celsion Corporation
                                 Condensed Statements of Operations
                                            (Unaudited)
                            (in thousands except for per share amounts)


                                  Three Months                Six Months
                                 Ended June 30,             Ended June 30,
                                 --------------             --------------
                                2010           2009     2010            2009
                                ----           ----     ----            ----
     Operating expenses:
       Research and
        development           $3,439         $4,230   $6,715          $7,172
       General and
        administrative         1,026            602    2,324           1,291
                               -----            ---    -----           -----
           Total operating
            expenses           4,465          4,832    9,039           8,463
                               -----          -----
     Loss from operations     (4,465)        (4,832)  (9,039)         (8,463)
                              ------         ------   ------          ------

     Other income
      (expense):
       Change in fair value
        of common stock
        warrant liability      1,829              -      259               -
       Other income
        (expense), net             5            241        5             255
                                 ---            ---      ---             ---
       Total other income
        (expense), net         1,834            241      264             255
                               -----            ---      ---             ---

     Net Loss                $(2,631)       $(4,591) $(8,775)        $(8,208)
                             =======        =======  =======         =======


    Net loss per common
     share - basic and
     diluted                  $(0.22)        $(0.45)  $(0.72)         $(0.81)
                              ======         ======   ======          ======

       Weighted average
        shares outstanding -
        basic and diluted     12,232         10,196   12,207          10,194
                              ======         ======   ======          ======




                                Celsion Corporation
                                   Balance Sheets
                    (in thousands except for per share amounts)


                                                      June 30,
    ASSETS                                                 2010  December 31,
                                                      (Unaudited)        2009
                                                      -----------        ----
     Current assets
       Cash and cash equivalents                            $2,745     $6,924
       Short term investments                                2,939      5,695
       Refundable income taxes                                   -        806
       Prepaid expenses and other receivables                  290        695
                                                               ---        ---
           Total current assets                              5,974     14,120
                                                             -----     ------

       Property and equipment                                  455        537
                                                               ---        ---

     Other assets
       Deposits                                                 84         97
       Other assets                                             47         51
                                                               ---        ---
           Total other assets                                  131        148
                                                               ---        ---

    Total assets                                            $6,560    $14,805
                                                            ======    =======

    LIABILITIES AND STOCKHOLDERS' EQUITY
     Current liabilities
       Accounts payable                                     $2,165     $2,191
       Other accrued liabilities                             1,468      1,452
       Note payable - current portion                          116        108
                                                               ---        ---
           Total current liabilities                         3,749      3,751

       Common stock warrant liability                          563        822
       Other liabilities - noncurrent                          126        197
                                                               ---        ---
           Total liabilities                                 4,438      4,770
                                                             -----      -----

     Stockholders' equity
       Common stock, $0.01 par value (75,000 shares
        authorized; 13,027                                     130        129
    and 12,895 shares issued and 12,267 and
     12,135 shares
    outstanding at June 30, 2010 and December
     31, 2009,
    respectively)
       Additional paid-in capital                           95,966     95,035
       Accumulated other comprehensive (loss)
        income                                                  (2)        68
       Accumulated deficit                                 (90,895)   (82,120)
                                                           -------    -------
             Subtotal                                        5,199     13,112
       Less: Treasury stock - at cost                       (3,077)    (3,077)
                                                            ------     ------
           Total stockholders' equity                        2,122     10,035
                                                             -----     ------

           Total liabilities and stockholders' equity       $6,560    $14,805
                                                            ======    =======



SOURCE Celsion Corporation

Copyright (C) 2010 PR Newswire. All rights reserved